Please login to the form below

Not currently logged in
Email:
Password:

Scancell appoints Dr Cliff Holloway as CEO

He joins the immunotherapy firm from Benitec Biopharma

Scancell Holdings, a group focused on the development of novel immunotherapies, has appointed Dr Cliff Holloway as its chief executive officer effective 10 January 2018.

Holloway’s new role will see him drive progress of Scancell’s immunotherapy platforms including ImmunoBody and Moditope, and oversee their commercialisation.

He said: “Having cemented a business relationship with Scancell in 2006 I have followed the company’s significant progress with great interest.

“I am delighted to be joining the Scancell team at this exciting time in the company’s evolution and look forward to building on the many achievements to date, and to progressing these important new cancer therapies for patients.”

With over 25 years’ experience in the life sciences industry, Holloway most joins from Benitec Biopharma, where he held the role of chief business and operating officer.

Prior to this, he was chief executive officer and managing director of Sienna Cancer Diagnostics, and has held roles for Immune System Therapeutics and Biosceptre International.

John Chiplin, executive chairman, Scancell, said: “Cliff’s extensive experience and accomplishments speaks volumes and his expertise in cancer therapeutics will be invaluable as we drive our immunotherapy vaccines through the clinic, with the aim to provide new treatment options for patients with debilitating cancers.”

Holloway succeeds Richard Goodfellow, who will remain on the company’s board of directors.

20th October 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt
...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again – in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics